PARP then modifies GAPDH, thereby reducing its activity. Finally, decreased GAPDH activity activates the polyol pathway, increases intracellular AGE formation, activates PKC and subsequently NFκB ...

Boehringer Ingelheim has slipped another piece of its oncology R&D strategy into place, partnering with Tessellate Bio on a ...

"Cancer cells can somehow tolerate the loss of the BRCA2 pathway, but when the PARP1 protein is inhibited, they die," he said. It remains unknown why the beneficial effects of PARP inhibitor ...

reduced GAPDH activity and inhibition of glycolytic flux through the activation of PARP, 3) escalation of the polyol and other collateral glycolysis pathways, 4) impaired hexokinase (HK ...

Scientific breakthroughs are transforming cancer treatments such as immuno-oncology, cell therapy and the synthetic lethal concept using poly (ADP-ribose) polymerase (PARP) inhibitors for breast ...

When mutations hinder BRCA2 function, cancer cells are known to rely on the poly ADP-ribose polymerase 1 (PARP1) pathway for backup DNA repair, and to continue abnormal growth. PARP inhibitors ...

By inhibiting PARP and blocking Wnt pathway activation, stenoparib’s unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer.

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...

Discover comprehensive insights into approved therapeutics and research developments targeting Prostate-Specific Membrane Antigen (PSMA). This product provides detailed competitor analysis, R&D stages ...

Boston (March 13, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated ...